切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2020, Vol. 14 ›› Issue (05) : 326 -329. doi: 10.3877/cma.j.issn.1674-3253.2020.05.002

专家论坛

上尿路尿路上皮癌的围手术期治疗现状
李志勇1, 刘卓炜1,()   
  1. 1. 525100 广东,中山大学肿瘤防治中心泌尿外科
  • 收稿日期:2020-03-03 出版日期:2020-10-10
  • 通信作者: 刘卓炜
  • 基金资助:
    国家自然科学基金项目(81772716)

Current status of perioperative treatment for upper urinary tract urothelial carcinoma

Zhiyong Li, Zhuowei Liu()   

  • Received:2020-03-03 Published:2020-10-10
  • Corresponding author: Zhuowei Liu
引用本文:

李志勇, 刘卓炜. 上尿路尿路上皮癌的围手术期治疗现状[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2020, 14(05): 326-329.

Zhiyong Li, Zhuowei Liu. Current status of perioperative treatment for upper urinary tract urothelial carcinoma[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2020, 14(05): 326-329.

[1]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in china, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[2]
Oupret M, Babjuk M, comperat E, et a1. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update[J]. Eur Urol, 2018, 73(1): 111-122.
[3]
方冬,黄吉炜,鲍一歌, 等. 中国上尿路尿路上皮癌人群特征和地区差异:基于CUDA-UTUC协作组的多中心研究[J]. 中华泌尿外科杂志, 2017, 38(2): 885-890.
[4]
Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration [J]. Cancer, 2009, 115(6): 1224-1233.
[5]
Cummings KB. Nephroureterectomy: rationale in the management of transitional cell carcinoma of the upper urinary tract [J]. Urol Clin North Am, 1980, 7(3): 569-578.
[6]
Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer[J]. N Engl J Med, 2003, 349(9): 859-866.
[7]
Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma[J]. Cancer, 2010, 116(13):3127-3134.
[8]
Liao RS, Gupta M, Schwen ZR, et al. Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma[J]. J Urol, 2018, 200(1): 68-73.
[9]
Foerster B, Abufaraj M, Petros F, et al. Efficacy of preoperative chemotherapy in high-risk upper tract urothelial carcinoma (UTUC)[J]. J Urol, 2020, 203(6): 101097
[10]
Porten, S, Siefker-Radtke AO, Xiao L, et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma[J]. Cancer, 2014, 120(12): 1794-1799.
[11]
Koie T, Ohyama C, Fujimoto H, et al. Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association[J]. Jpn J Clin Oncol, 2016, 46(5): 468-474.
[12]
Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration[J]. Cancer, 2009, 115(6): 1224-1233.
[13]
Favaretto RL, Shariat SF, Chade DC, et al. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?[J]. Eur Urol, 2010, 58(5): 645-651.
[14]
Ni S1, Tao W, Chen Q, et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies[J]. Eur Urol, 2012, 61(6): 1142-1153.
[15]
Simone G, Papalia R, Guaglianone S, et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study[J]. Eur Urol, 2009, 56(3): 520-526.
[16]
Aboumohamed AA, Krane LS, Hemal AK. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma[J]. J Urol, 2015, 194(6): 1561-1566.
[17]
Seisen T, Peyronnet B, Dominguez-Escrig JL, et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the eau nonmuscle invasive bladder cancer guidelines panel[J]. Eur Urol, 2016, 70(6): 1052-1068.
[18]
Zareba P, Rosenzweig B, Winer AG, et al. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract[J]. Cancer, 2017, 123(10): 1741-1750.
[19]
Dominguez-Escrig JL, Peyronnet B, Seisen T, et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the european association of urology guidelines panel on non-muscle-invasive bladder cancer[J]. Eur Urol Focus, 2017, 5(2): 224-241.
[20]
O'Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol, 2011, 60(4): 703-710.
[21]
Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial[J]. J Clin Oncol, 2013, 31(11): 1422-1427.
[22]
梁华民,齐文旭,张明. 上尿路尿路上皮癌手术后单次与多次膀胱灌注化疗对发生膀胱癌的影响[J]. 中国药物与临床2019, 19(5): 74-756
[23]
Czito B, Zietman A, Kaufman D, et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter[J]. J Urol, 2004, 172(4 Pt 1): 1271-1275.
[24]
Seisen T, Krasnow RE, Bellmunt J, et al. Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma[J]. J Clin Oncol, 2017, 35(8): 852-860.
[25]
Birtle, AJ, Chester, JD, Jones RJ, et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC) [J]. J Clin Oncol, 2018, 36 (6_suppl): 407.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 王聪, 李云涛, 唐甜甜, 王鑫蕊, 吕鑫, 范志刚. 多基因检测对激素受体阳性、HER-2阴性乳腺癌新辅助化疗疗效预测的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 292-296.
[3] 宋玟焱, 杜美君, 陈佳丽, 石冰, 黄汉尧. 唇腭裂手术围手术期疼痛管理的研究进展及基于生物材料治疗新方法的展望[J/OL]. 中华口腔医学研究杂志(电子版), 2024, 18(06): 397-405.
[4] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[5] 宋小飞, 巫嘉文, 孙阳. 输尿管开口周围膀胱黏膜预离断联合早期膀胱灌注化疗在上尿路尿路上皮癌根治术中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 479-484.
[6] 吴伟宙, 王琼仁, 詹雄宇, 郑明星, 李亚县. 广东省医学会泌尿外科疑难病例多学科会诊(第16期)——左肾肉瘤样癌[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 525-529.
[7] 井发红, 李丽娜, 高婷, 高艳梅, 杨楠, 李卓, 慕玉东. 肺癌立体定向放疗血清SAP 和MMPs 表达及临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 707-713.
[8] 张昊, 潘卫东. 胰腺癌新辅助化疗后可切除性评估现状及进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 629-633.
[9] 王军华, 王锐炫. 胰腺癌新辅助化疗现状和治疗策略[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 640-643.
[10] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-肛管癌(2024 版)[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 441-449.
[11] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[12] 石阳, 于剑锋, 曹可, 翟志伟, 叶春祥, 王振军, 韩加刚. 可扩张金属支架置入联合新辅助化疗治疗完全梗阻性左半结肠癌围手术期并发症分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 464-471.
[13] 梁轩豪, 李小荣, 李亮, 林昌伟. 肠梗阻支架置入术联合新辅助化疗治疗结直肠癌急性肠梗阻的疗效及其预后的Meta 分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 472-482.
[14] 唐玉天, 王艳芝, 王毅, 任益民, 张雁山, 赵文学, 王芳, 杨文源. HFOV 控制胸腹部肿瘤碳离子精准治疗患者呼吸运动的安全性分析[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 344-350.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?